RecruitingNCT07096999
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Sponsor
University of Michigan Rogel Cancer Center
Enrollment
60 participants
Start Date
Jan 23, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria5
- \* 177Lu-617 PSMA treatment scheduled for mCRPC
- Clinically stable as determined by the nuclear medicine clinicians
- Male
- ≥ 18 years of age
- Willing and able to provide informed consent
Exclusion Criteria1
- Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07096999
Related Trials
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
NCT0407123632 locations
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
NCT065262993 locations